A randomized, multicenter, double-blind, placebo-controlled, Phase 3 study of the Bruton's Tyrosine Kinase inhibitor ibrutinib in combination with nab-paclitaxel and gemcitabine versus placebo in combination with nab-paclitaxel and gemcitabine, in the first line treatment of patients with metastatic pancreatic adenocarcinoma

Trial Profile

A randomized, multicenter, double-blind, placebo-controlled, Phase 3 study of the Bruton's Tyrosine Kinase inhibitor ibrutinib in combination with nab-paclitaxel and gemcitabine versus placebo in combination with nab-paclitaxel and gemcitabine, in the first line treatment of patients with metastatic pancreatic adenocarcinoma

Active, no longer recruiting
Phase of Trial: Phase II/III

Latest Information Update: 24 Sep 2017

At a glance

  • Drugs Ibrutinib (Primary) ; Gemcitabine; Paclitaxel
  • Indications Adenocarcinoma; Pancreatic cancer
  • Focus Therapeutic Use
  • Acronyms RESOLVE
  • Sponsors Pharmacyclics
  • Most Recent Events

    • 04 Apr 2017 Status changed from recruiting to active, no longer recruiting.
    • 17 Jan 2017 Planned number of patients changed from 326 to 426.
    • 07 Jun 2016 Trial design presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top